Registered title, quoted from ClinicalTrials.gov
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
An open trial on multiple myeloma and B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07113496, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Pathologically confirmed CD19-positive and/or B-cell maturation antigen (BCMA)-positive hematologic malignancy according to the WHO 2017 classification, including but not limited to multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphomas, and plasmablastic lymphoma.
Inclusion criterion 2
Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
Inclusion criterion 13
Total bilirubin <2× upper limit of normal (ULN); serum creatinine <ULN; ALT and AST <3× ULN.
Inclusion criterion 11
Absolute neutrophil count ≥0.5×10⁹/L; platelets ≥20×10⁹/L (no requirement if marrow involvement is documented).
Inclusion criterion 12
For lymphoma: at least one measurable lesion ≥1.5 cm in longest diameter per IWG revised criteria.
Inclusion criterion 6
Pregnancy, lactation, or planned pregnancy within 6 months.
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07113496, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria
- Voluntary participation with signed informed consent.
- Pathologically confirmed CD19-positive and/or B-cell maturation antigen (BCMA)-positive hematologic malignancy according to the WHO 2017 classification, including but not limited to multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphomas, and plasmablastic lymphoma.
- Relapsed/refractory disease defined as failure to achieve complete remission after standard therapy, or relapse after an initial response during treatment or follow-up.
- Measurable disease required:
- For B-ALL: persistent minimal residual disease (MRD) positivity despite hematologic remission.
- For lymphoma: at least one measurable lesion ≥1.5 cm in longest diameter per IWG revised criteria.
- For multiple myeloma: positive immunofixation electrophoresis or presence of extramedullary disease.
- Age ≥18 years; both sexes eligible.
- Expected survival ≥12 weeks.
- Adequate organ function (exceptions for disease-related impairment are at the investigator's discretion):
- Total bilirubin <2× upper limit of normal (ULN); serum creatinine <ULN; ALT and AST <3× ULN.
- Absolute neutrophil count ≥0.5×10⁹/L; platelets ≥20×10⁹/L (no requirement if marrow involvement is documented).
- Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Left ventricular ejection fraction (LVEF) ≥50%.
Exclusion Criteria
- Known hypersensitivity, allergy, intolerance, or contraindication to CD19/BCMA-UCAR-T or any study drugs (fludarabine, cyclophosphamide, tocilizumab).
- Genetic syndromes: Fanconi, Kostmann, Shwachman, or any documented bone-marrow failure syndrome.
- Active or uncontrolled infection requiring IV antibiotics; evidence of severe active infection.
- NYHA Class III or IV heart failure (unless clearly secondary to the underlying malignancy).
- Central Nervous System (CNS) disorders unrelated to the primary hematologic malignancy.
- Prior malignancy except adequately treated carcinoma in situ of skin, cervix, lung, or other non-active tumors.
- Significant bleeding diathesis (e.g., gastrointestinal (GI) bleeding, coagulopathy, hypersplenism).
- History of significant cardiac disease within the past 3 months that, in the investigator's judgment, renders the patient unable to tolerate study participation..
- Pregnancy, lactation, or planned pregnancy within 6 months.
- Any condition that, in the investigator's opinion, may increase risk or interfere with study results.
Quoted from ClinicalTrials.gov, NCT07113496, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07113496, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.